Orchard Therapeutics PLC – (NASDAQ:ORTX) Given Consensus Rating of “Buy” by Brokerages

Share on StockTwits

Shares of Orchard Therapeutics PLC – (NASDAQ:ORTX) have been given an average rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $26.20.

Several equities research analysts have recently weighed in on the company. Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Orchard Therapeutics in a research report on Monday, December 2nd. Zacks Investment Research cut Orchard Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, ValuEngine raised Orchard Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 6th.

In related news, insider Fmr Llc sold 19,721 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.49, for a total value of $266,036.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Several hedge funds and other institutional investors have recently modified their holdings of ORTX. Citigroup Inc. acquired a new position in Orchard Therapeutics during the fourth quarter worth $42,000. Lindbrook Capital LLC raised its stake in Orchard Therapeutics by 40.0% during the fourth quarter. Lindbrook Capital LLC now owns 3,500 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares in the last quarter. Fred Alger Management LLC acquired a new position in Orchard Therapeutics during the fourth quarter worth $69,000. Marshall Wace North America L.P. acquired a new position in Orchard Therapeutics during the fourth quarter worth $105,000. Finally, Trexquant Investment LP acquired a new position in Orchard Therapeutics during the fourth quarter worth $151,000. Institutional investors and hedge funds own 67.55% of the company’s stock.

ORTX opened at $12.60 on Friday. Orchard Therapeutics has a 1-year low of $9.78 and a 1-year high of $21.64. The company has a current ratio of 8.88, a quick ratio of 8.88 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.23 and a beta of -0.99. The business has a 50 day moving average of $13.65 and a 200-day moving average of $13.10.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Read More: What does a market perform rating mean?

Analyst Recommendations for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Celcuity  Raised to “Buy” at Zacks Investment Research
Celcuity Raised to “Buy” at Zacks Investment Research
Centennial Resource Development  Rating Increased to Sell at BidaskClub
Centennial Resource Development Rating Increased to Sell at BidaskClub
Avis Budget Group  Rating Increased to Sell at ValuEngine
Avis Budget Group Rating Increased to Sell at ValuEngine
Cheesecake Factory  PT Lowered to $42.00 at Cfra
Cheesecake Factory PT Lowered to $42.00 at Cfra
Barclays Cuts Cheesecake Factory  Price Target to $36.00
Barclays Cuts Cheesecake Factory Price Target to $36.00
Bank of America Trims Cheesecake Factory  Target Price to $43.00
Bank of America Trims Cheesecake Factory Target Price to $43.00


 
© 2006-2020 Zolmax.